
Had a wonderful afternoon playing monopoly supporting the #LittleLegsFoundation for beautiful Alegra. Thank you for all you do to support #dunlab and DIPG research. @evierjackson @mika persson

DIPG scientist | Underwater exploration | #DunLab post doc | rundipg.org

Had a wonderful afternoon playing monopoly supporting the #LittleLegsFoundation for beautiful Alegra. Thank you for all you do to support #dunlab and DIPG research. @evierjackson @mika persson

So great to see our review article on targeting CLPP out in print. Beautiful work from @evierjackson, @Mika_Persson97 and @MattDun17.
Huge congrats to @evierjackson @Mika_Persson97 & @duchatel_ryan for leading this & #DunLab team & wonderful #DMG #DIPG colleagues for your support. "Current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered" academic.oup.com/neuro-oncol…

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma: buff.ly/3TAz4Jd @MattDun17 @childrenshealth @Uni_Newcastle #Oncology #Therapeutics

Thank you @RobertReya for the fantastic and considered commentary on our recent @jclinicalinvest publication on PI3K/PKC in DIPG/DMG. jci.org/articles/view/179144

Proud to see our paper targeting PI3K in DMG on the cover of JCI. Thank you to all those who assisted this work, in particular my amazing colleague @evierjackson and mentor @MattDun17.
#Cover: Targeting PI3K/mTOR in diffuse intrinsic pontine glioma: buff.ly/3TAz4Jd #Image presents a model whereby the connectivity of these cancers can be harnessed using integrated technologies to identify potential therapeutic strategies. #Oncology #Therapeutics

#Cover: Targeting PI3K/mTOR in diffuse intrinsic pontine glioma: buff.ly/3TAz4Jd #Image presents a model whereby the connectivity of these cancers can be harnessed using integrated technologies to identify potential therapeutic strategies. #Oncology #Therapeutics

Thank you @CureStartsNow @CureStartsNowAU for the Valentine’s Day treats!


This project was truly collaborative, with a number of researchers and groups contributing from across many countries. @DKiltschewskij, @DilanaStaudt, @Bryce_Thomas23, @Zacger, @DrLizzieManning, @DeVerrills, @DavidSkerrettB, @BrettNixon13, @DrSusanHua, @charles_debock (10/11)

Thank you to all those who funded and supported our research, including @chadtough, @RUNDIPG, @DIPGCollab, @CureStartsNow, @CureStartsNowAU, @_IsabellaMarcus, @KidsCancerProj, @tourdecure_aus, @livlikeaunicorn, @nhmrc, @Uni_Newcastle, @HMRIAustralia . (9/11)

Together, we have identified a clinically relevant therapeutic combinatorial approach for DIPG/DMG that we hope to see tested in clinical trials. (8/11)

We performed the first @10xGenomics Xenium spatial transcriptomics of DIPG/DMG models, identifying the combination of paxalisib and enzastaurin adapted to therapy through STAT1 expression and an increased MHCII phenotype providing impetus for further studies. (7/11)

As radiation therapy is still the mainstay of DIPG/DMG treatment, we showed the utility of paxalisib and enzastaurin in combination with up front RT. (6/11)

The combination of paxalisib and the PKC inhibitor Enzastaurin synergistically extended the survival of a number of aggressive pre-clinical DIPG/DMG models. (5/11)

To identify rational combination strategies to enhance PI3K inhibition we integrated RNA-seq and quantitative phosphoproteomic profiling, and identified the activation of Protein Kinase C (PKC) in DIPG/DMG cells when treated with Paxalisib. (4/11)

Clinically, resistance to PI3K inhibitors is mediated by insulin feedback caused by hyperglycemic side effects following PI3K inhibition. Paxalisib in combination with the anti-glycemic drug metformin reduced these side effects and improved efficacy in pre-clinical models. (3/11)